Volume 11, Issue 3 (2025)                   Pharm Biomed Res 2025, 11(3): 237-250 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hatampour H, Jamshidi H R, Aghazadeh-Habashi K, Rafatmagham S, Farnaghi F, Ghasemirad H, et al . Clinical and Prognostic Findings in Psychotropic Substance Poisoning: A Cross-sectional Study. Pharm Biomed Res 2025; 11 (3) :237-250
URL: http://pbr.mazums.ac.ir/article-1-660-en.html
1- Department of Pharmacology, School of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
2- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
3- Department of Internal Medicine, Fasa University of Medical Sciences, Fasa, Iran.
4- Department of Psychiatry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
5- Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
6- Social Security Organization of Yazd, Yazd, Iran.
7- Faculty of Dentistry, Isfahan Branch, Islamic Azad University, Isfahan, Iran.
8- Department of Forensic Medicine & Clinical Toxicology, Yazd Branch, Islamic Azad University, Yazd, Iran.
Abstract:   (700 Views)
Background: Psychotropic substance poisoning is a growing public health concern. 
Objectives: This study aimed to investigate patients with psychedelic poisoning and evaluate the frequency of clinical, preclinical, and prognostic findings.
Methods: This retrospective cross-sectional study extracted clinical findings of patients, including neurological findings, cardiovascular findings, preclinical findings, treatment measures, and prognosis of patients poisoned with psychoactive substances who were admitted to Shah Vali Hospital in Yazd Province, Iran, and Shaheed Beheshti Hospital in Taft City, Iran, from 2014 to 2023 from their medical records and the hospital information system (HIS).
Results: In the present study, information was extracted from 311 patients with psychotropic intoxication, comprising 164 individuals who had used stimulants and 147 who had used hallucinogens. The highest frequency of stimulant use was related to glass, with 160 individuals (51.4%), and the highest frequency of hallucinogen use was related to hashish, with 138 individuals (44.4%). Notably, most patients survived (99.67%). The most common symptoms observed were increased blood pressure (BP) (28.2%), mydriasis (73.31%), tachycardia (77.9%), shock (1.9%), seizures (5.5%), and agitation (68.16%). Elevated creatine phosphokinase (CPK) levels were observed in 3.53% of patients, and the severity of intoxication was statistically significant (P=0.001). The results also showed a significant difference in the frequency distribution of psychoactive substances (stimulants and hallucinogens) according to the route of consumption (oral vs inhalation). Specifically, most psychoactive substances (both stimulants and hallucinogens) were inhaled rather than ingested (P<0.01). Also, a significant difference was observed in the frequency distribution of individuals poisoned with psychedelics (stimulants and hallucinogens) according to the reason for consumption (suicide vs abuse) (P>0.01). In this regard, the most common reason for consumption was abuse (70.1%). The frequency distribution of treatment types among patients poisoned with psychotropic drugs (stimulants and hallucinogens) showed that benzodiazepines were the most frequently used treatment (73%).
Conclusion: This study of 311 patients with psychedelic poisoning reveals a significant prevalence of substance abuse, particularly among younger males, with stimulants being the most commonly used drugs. These findings underscore the urgent need for targeted prevention and intervention programs to address the critical issue of psychotropic substance misuse among at-risk populations.
Full-Text [PDF 692 kb]   (146 Downloads) |   |   Full-Text (HTML)  (118 Views)  
Type of Study: Original Research | Subject: Toxicology

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2026 CC BY-NC 4.0 | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb